Original Research
The intravenous pharmacokinetics of diminazene in healthy dogs
V. Naidoo, M.S.G. Mulders, G.E. Swan
Journal of the South African Veterinary Association | Vol 80, No 4 | a210 |
DOI:
https://doi.org/10.4102/jsava.v80i4.210
| © 2009 Copyright Status: Not provided. Contact Holding Institution to verify copyright status. Rights Holder: South African Veterinary Association
Submitted: 25 May 2009 |
Published: 28 May 2009
About the author(s)
V. Naidoo,
M.S.G. Mulders,
G.E. Swan,
Abstract
Diminazene remains one of South Africa's most commonly used antiprotozoal agents for the management of babesiosis in dogs . Although the drug has been on the market for over 40 years, its intravenous pharmacokinetics are poorly known. To better understand the pharmacokinetics of the drug Berenil®, it was reconstituted in sterile water and administered intravenously to 6 adult German shepherd dogs. All 6 dogs demonstrated the previously described secondary peak in the plasma concentration versus time profile. The plasma pharmacokinetics for diminazene are described by both non-compartmental and compartmental models. From non-compartmental analysis, the area under curve to the last sample point (AUClast), clearance (CL) and volume of distribution (Vz) were 4.65±1.95 ng/mℓ/h, 0.77±0.18 ℓ/kg/h and 2.28±0.60 ℓ/kg, respectively. For compartmental modelling, the plasma concentrations were fitted to both a 2-compartmental open model and a recirculatory enterohepatic model. From the recirculation model, the rate of release and re-entry into the central compartment varied markedly with the rate of release from the gall bladder (Ttom) being estimated at 27 ± 20.90 h. Once released, drug re-entry into the central compartment was variable at 9.70±5.48 h. With normal biliary excretion time being about 2 h, this indicates that the redistribution cannot be occurring physiologically from the bile. Although it was not possible to identify the site from which sequestration and delayed release is occurring, it is believed that it is most likely from the liver. The study therefore showed that the secondary peak described for the pharmacokinetics of intramuscular administered diminazene in the dog is not related to biphasic absorption.
Keywords
Berenil®; Dog; Enterohepatic; Intravenous; Pharmacokinetics; PK40; Eecirculation
Metrics
Total abstract views: 4115
Total article views: 2991
Crossref Citations
1. Diminazene aceturate poisoning in a dog (Canis familiaris) treated for visceral leishmaniasis
Nayara Toledo da Silva, Acácia Eduarda de Jesus Nascimento, Lucas dos Reis de Souza, Benito Soto-Blanco, Ayisa Rodrigues Oliveira
Brazilian Journal of Veterinary Pathology vol: 17 issue: 3 first page: 207 year: 2024
doi: 10.24070/bjvp.1983-0246.v17i3p207-212
2. Improved clearance of radioiodinated hypericin as a targeted anticancer agent by using a duodenal drainage catheter in rats
Marlein Miranda Cona, Yuanbo Feng, Alfons Verbruggen, Raymond Oyen, Yicheng Ni
Experimental Biology and Medicine vol: 238 issue: 12 first page: 1437 year: 2013
doi: 10.1177/1535370213508235
3. Clinical and therapeutic aspects of an outbreak of canine trypanosomiasis
Jessica Teles Echeverria, Rodrigo Leite Soares, Beatriz Aléssio Crepaldi, Gustavo Gomes de Oliveira, Polyana Mayume Pereira da Silva, Rayane Chitolina Pupin, Tessie Beck Martins, Herbert Patric Kellermann Cleveland, Carlos Alberto do Nascimento Ramos, Fernando de Almeida Borges
Revista Brasileira de Parasitologia Veterinária vol: 28 issue: 2 first page: 320 year: 2019
doi: 10.1590/s1984-29612019018
4. Aspectos epidemiológicos, clínicos e anatomopatológicos da intoxicação por aceturato de diminazeno em cães
Mariana M. Flores, Paula R. Pereira, Alexandre Mazzanti, Glaucia D. Kommers, Rafael A. Fighera
Pesquisa Veterinária Brasileira vol: 34 issue: 7 first page: 667 year: 2014
doi: 10.1590/S0100-736X2014000700011
5. Diminazene-induced encephalopathy in dogs: Case series and treatment with crisdesalazine
Yeonsoo Lee, YoungMin Yun, Woo-Jin Song
Korean Journal of Veterinary Service vol: 48 issue: 2 first page: 167 year: 2025
doi: 10.7853/kjvs.2025.48.2.167